新型mRNA疫苗在治療皮膚癌方面展現潛力
New mRNA Vaccine Shows Promise in Treating Skin Cancer
Updated at: August 26, 2026 at 12:45 AM
一項開創性的醫學研究為對抗黑色素瘤的患者帶來了新希望。
A groundbreaking medical study has brought new hope to patients fighting melanoma.
Moderna與默克(Merck)攜手合作的一個計畫，成功測試了一種名為mRNA-4157的個性化mRNA癌症疫苗，旨在預防皮膚癌復發。
A collaborative project between Moderna and Merck has successfully tested a personalized mRNA-based cancer vaccine, known as mRNA-4157, designed to prevent the recurrence of skin cancer.
在一項大型第三期臨床試驗中，研究人員發現，將此疫苗與免疫治療藥物Keytruda結合使用，與僅單獨使用該藥物相比，能顯著降低癌症復發或擴散的機率。
In a large Phase 3 clinical trial, researchers found that combining this vaccine with the immunotherapy drug Keytruda significantly lowered the chances of the cancer returning or spreading compared to using the drug alone.
不同於預防傳染病的傳統疫苗，這種治療方法具有高度的個性化。
Unlike traditional vaccines that prevent infectious diseases, this treatment is highly personalized.
一旦注射，mRNA會指導人體訓練免疫系統識別獨特的腫瘤突變，從而找出並消滅殘留的癌細胞。
Once injected, the mRNA instructs the body to identify and destroy remaining cancer cells by training the immune system to recognize unique tumor mutations.
隨後，Keytruda會協助免疫系統更有效地攻擊這些細胞。
Keytruda then helps the immune system attack these cells more effectively.
儘管這種治療仍處於實驗階段，但這些結果代表了腫瘤學上的一個歷史性里程碑。
While this treatment is still in the experimental stages, the results represent a historic milestone in oncology.
這證明了在COVID-19疫情期間使用的同一種mRNA技術，也能被應用於治療實體腫瘤，並有可能在未來改變我們治療肺癌、乳癌和胰臟癌的方式。
It proves that the same mRNA technology used during the COVID-19 pandemic can be adapted to treat solid tumors, potentially changing how we treat lung, breast, and pancreatic cancers in the future.
